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Secondary prevention of coronary heart disease in older
patients after the national service framework: population
based study
Sheena E Ramsay, Peter H Whincup, Debbie A Lawlor, Olia Papacosta, Lucy T Lennon,
Mary C Thomas, Shah Ebrahim, Richard W Morris
Abstract
Objective To examine the extent of uptake of
medication for secondary prevention of coronary
heart disease in older British men and women before
(1998-2001) and after (2003) the implementation of
the national service framework.
Design Two population based, longitudinal studies of
men and women aged 60-79 in 1998-2001, based in
one general practice in each of 24 British towns.
Participants Men and women with established
coronary heart disease at the two time points
(respectively 817 and 465 in 1998-2001, 857 and
548 in 2003), aged 60-79 in 1998-2001.
Main outcome measures Prevalence of use of
antiplatelet medication, statins,  blockers, angiotensin
converting enzyme (ACE) inhibitors, and other blood
pressure lowering treatments (individually and in
combination) assessed in 1998-2001 and 2003.
Results Between 1998-2001 and 2003, the use of all
individual drugs had increased in both men and
women, especially for statins (from 34% to 65% in
men and from 48% to 67% in women with myocardial
infarction). However, less than half received  blockers
and ACE inhibitors, even by 2003. Prevalences of
medication use were lower in patients with angina
than in those with myocardial infarction. The
proportions of patients receiving more than one drug
increased over time; by 2003 about half of patients
with myocardial infarction and a third of those with
angina were receiving antiplatelet medication, statins,
and blood pressure lowering treatments.
Conclusions Between 1998-2001 and 2003, statin
uptake and the use of combined drug treatment in
elderly men and women increased markedly. Further
potential exists, however, for reducing the risk of
recurrent coronary heart disease in older patients,
particularly by improving the uptake of medication
among angina patients, and by more extensive use of
blood pressure lowering treatment (particularly with
 blockers and ACE inhibitors).
Introduction
Secondary prevention of coronary heart disease is an
important component of the national service frame-
work for coronary heart disease.1 Recently it has been
increasingly recognised that using drugs in combina-
tion (particularly antiplatelet medication, statins, and
blood pressure lowering drugs) could produce
substantial relative reductions in the risk of coronary
heart disease of up to 75% or more.2 Most published
reports of secondary prevention in the United
Kingdom are based on data predating the national
service framework in 2000. We used two longitudinal
studies to examine the extent of uptake of secondary
prevention (including combination treatment) in older
British men and women before and after the
implementation of the national service framework.
Methods
The British regional heart study and the British wom-
en’s heart and health study are population based stud-
ies of cardiovascular disease in British towns represent-
ing all major British regions.3 4 We reviewed general
practice records every two years to obtain information
on diagnoses of coronary heart disease. We used ques-
tionnaires in 1998-2000 (mid-year 1999; response rate
77%) and 2003 (80%) in the men’s study, and
1999-2001 (mid-year 2000; 60%) and 2003 (90%) in
the women’s study to collect data on medication use.
We examined the prevalence of medication use among
prevalent coronary heart disease cases at each time
point; the populations differed slightly, supplemented
by new coronary heart disease cases and attenuated by
death and non-response.
Results
Between 1998-2001 and 2003, the prevalence of use of
all individual drugs had increased in both men and
women, especially for statins, which doubled in usage
(table). Prevalences of medication use were very similar
in men and women, with the exception of antiplatelet
drugs, which were consistently lower in women. In
2003, although about 80% of men and women with a
history of myocardial infarction were taking antiplate-
let medication, only two thirds were receiving statins,
and less than half were receiving  blockers and ACE
inhibitors. Prevalences of medication use were
generally lower in patients with angina than in patients
with myocardial infarction.
By 2003, more than 90% of subjects with
myocardial infarction and more than 80% of those
with angina were receiving at least one medication.
The number of patients receiving more than one drug
had increased, and by 2003 about half of patients with
myocardial infarction and a third of those with angina
were receiving three drug classes.
Discussion
Between 1998-2001 and 2003, statin uptake and the
use of combinations of drugs in elderly men and
women increased markedly; a key publication high-
lighting likely benefits of combination treatment
appearedmid-way through 2003.2 By 2003, antiplatelet
This article was posted on bmj.com on 9 January 2006: http://bmj.com/
cgi/doi/10.1136/bmj.38704.770127.BE
Research
Department of
Primary Care and
Population
Sciences, Royal Free
and University
College Medical
School, London
NW3 2PF
Sheena E Ramsay
research fellow
Peter H Whincup
professor of
cardiovascular
epidemiology
Olia Papacosta
research statistician
Lucy T Lennon
research
administrator
Mary C Thomas
research assistant
Richard W Morris
reader in medical
statistics
Department of
Social Medicine,
University of
Bristol, Bristol
BS8 2PR
Debbie A Lawlor
senior lecturer in
epidemiology and
public health medicine
Shah Ebrahim
professor in
epidemiology of
ageing
Correspondence to:
S E Ramsay
s.ramsay@
pcps.ucl.ac.uk
BMJ 2006;332:144–5
144 BMJ VOLUME 332 21 JANUARY 2006 bmj.com
drugs and statins were very widely used (particularly in
patients with myocardial infarction). These data from
representative samples of older men and women in
primary care settings should be widely representative.
By limiting analyses to subjects with confirmed general
practitioner diagnoses, the study should avoid biases
arising from using self reported diagnoses of coronary
heart disease. Self reported use of medication was
probably a more valid indication of medication usage
but may not equate to medications prescribed. The
methods used at both time points were identical, and
the observed increase in secondary prevention over
this time period is therefore likely to reflect a real
change in clinical practice. Although subjects had aged
by three to four years between the surveys, this is
unlikely to explain the change, because older subjects
are less likely to receive secondary prevention medica-
tion.3 Further potential exists for reducing the risk of
recurrent coronary heart disease in older patients, par-
ticularly by improving the uptake of medication
among patients with angina, and by more extensive use
of blood pressure lowering treatment,  blockers, and
ACE inhibitors.
Contributors: SER, PHW, and RWM developed the original idea
for the paper, and SER wrote the first draft. SER, OP, and DAL
performed the analyses. PHW, RWM, MCT, LTL, and SE
contributed to the design and execution of the British Regional
Heart Study, and DAL and SE to the design and execution of the
British women’s heart and health study. All authors contributed
to interpretation of data and the final version of the manuscript,
and all are guarantors.
Funding: The British regional heart study and the British wom-
en’s heart and health study are funded by the Department of
Health, England. The British Regional Heart Study is also a
British Heart Foundation Research Group. DAL is funded by a
career scientist award from the UK Department of Health.
Competing interests: None declared.
Ethical approval: The British regional heart study and the Brit-
ish women’s heart and health study have local (from each of the
districts in which the study was based) and multicentre ethical
committee approvals.
1 Department of Health. National service framework for coronary heart disease.
London: DoH, 2000.
2 Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more
than 80%. BMJ 2003;326:1419.
3 Lawlor DA, Whincup PH, Emberson JR, Rees K, Walker M, Ebrahim S.
The challenge of secondary prevention for coronary heart disease in
older patients: findings from the British women’s heart and health study
and the British regional heart study. Fam Pract 2004;21:582-6.
4 Walker M, Whincup PH, Shaper AG. The British regional heart study
1975-2004. Int J Epidemiol 2004;33:1185-92.
(Accepted 14 November 2005)
doi 10.1136/bmj.38704.770127.BE
Prevalence of medication use for secondary prevention in patients with myocardial infarction or angina. Values are numbers
(percentages) of patients unless otherwise indicated
Myocardial infarction Angina
Men Women Men Women
1998-2000
(n=332)
2003
(n=336)
1999-2001
(n=91)
2003
(n=109)
1998-2000
(n=485)
2003
(n=521)
1999-2001
(n=374)
2003
(n=439)
No of subjects at both time points 283 87 412 352
Individual treatment
Antiplatelet drugs 272 (82) 297 (88) 64 (70) 85 (78) 318 (66) 395 (76) 162 (43) 255 (58)
Statins 112 (34) 219 (65) 44 (48) 73 (67) 106 (22) 257 (49) 92 (25) 197 (45)
 blockers 118 (36) 147 (44) 33 (36) 46 (42) 143 (30) 190 (37) 116 (31) 167 (38)
Angiotensin converting enzyme (ACE)
inhibitors
92 (28) 147 (44) 26 (29) 35 (32) 81 (17) 155 (30) 75 (20) 135 (31)
Blood pressure lowering drugs other
than  blockers or ACE inhibitors*
135 (41) 150 (45) 9 (10) 16 (15) 202 (42) 252 (48) 73 (20) 89 (20)
Combination treatment†
No drug 19 (6) 8 (2) 14 (15) 9 (8) 85 (18) 55 (10) 94 (25) 60 (14)
Any 1 category 80 (24) 39 (12) 21 (23) 12 (11) 140 (29) 88 (17) 147 (39) 105 (24)
Any 2 categories 160 (48) 115 (34) 38 (42) 32 (29) 195 (40) 196 (38) 96 (26) 136 (31)
Any 3 categories 73 (22) 174 (52) 18 (20) 56 (51) 65 (13) 182 (35) 37 (10) 138 (31)
*Includes thiazides, diuretics with potassium, vasodilator drugs, centrally acting antihypertensive drugs, adrenergic neurone blocking drugs,  blockers, angiotensin
II antagonists, ganglion blocking drugs, tyrosine hydroxylase inhibitors, and calcium channel blockers.
†Antiplatelet drugs, statins, blood pressure lowering drug (angiotensin converting enzyme (ACE) inhibitor,  blocker), and blood pressure lowering drugs other than
 blockers or ACE inhibitors.
What is already known on this topic
Combinations of treatment for secondary
prevention of coronary heart disease (antiplatelet
medication, statins, and antihypertensive drugs)
reduce the risk of coronary heart disease
substantially, but the extent of their use is not
known
What this study adds
Uptake of secondary prevention increased
markedly between 1998-2001 and 2003; by 2003
half of patients with myocardial infarction were
using a combination of antiplatelet medication,
statins, and blood pressure lowering drugs
Despite this, considerable opportunities remain
for improving completeness of secondary
prevention, especially in patients with angina
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